QUINAZOLINE COMPOUNDS

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds. 2. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H claim 1 , —CN claim 1 , —OR claim 1 , or Calkyl.3. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CN.4. (canceled)6. (canceled)7. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein X claim 1 , X claim 1 , and Xare each CH.8. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein Xis N; Xis CH; and Xis CH.9. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein X claim 1 , X claim 1 , and Xare C(R); each Rare independently selected from —H claim 1 , —CN claim 1 , —OR claim 1 , halogen claim 1 , and Calkyl; and Ris selected from —H claim 1 , —CN claim 1 , —OR claim 1 , halogen claim 1 , and Calkyl.10. (canceled)11. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —H claim 1 , —OR claim 1 , —NRR claim 1 , —NHC(O)NRR claim 1 , Calkyl claim 1 , or Cheteroalkyl.12. (canceled)13. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —NHor —OH.1418-. (canceled)19. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein two of R claim 1 , R claim 1 , and Rare —H and one of R claim 1 , R claim 1 , and Ris —H claim 1 , —OR claim 1 , halogen claim 1 , —NO claim 1 , —CN claim 1 , —NRR claim 1 , —NHC(O)NRR claim 1 , or Calkyl.2021-. (canceled)22. The compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof claim 1 , wherein R claim 1 , R claim 1 , and Rare —H.23. The compound of ...

Isoquinoline Compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

IMIDAZOPYRAZINE SYK INHIBITORS

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of an imidazopyrazine compound effective to reduce signs or symptoms of the disease or disorder are provided. 3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein Ris:unsubstituted morpholinyl,substituted morpholinyl with one, two or three substituents independently selected from the group consisting of unsubstituted alkyl and substituted alkyl;unsubstituted piperazinyl; orsubstituted piperazinyl with one, two or three substituents independently selected from the group consisting of unsubstituted alkyl, substituted alkyl, unsubstituted heterocycloalkyl, and substituted heterocycloalkyl.5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein:X is N or CH;{'sup': 'a', 'Ris methoxy;'}{'sup': 'b', 'Ris unsubstituted morpholinyl, substituted morpholinyl, unsubstituted piperazinyl or substituted piperazinyl; and'}n is 0 or 1.9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , wherein Ris:unsubstituted phenyl;substituted phenyl with one or two substituents independently selected from the group consisting of unsubstituted alkyl, substituted alkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted alkoxy, substituted alkoxy, unsubstituted cycloalkyloxy, substituted cycloalkyloxy, unsubstituted heterocycloalkyloxy, substituted heterocycloalkyloxy, unsubstituted amino, substituted amino, unsubstituted sulfonyl, substituted sulfonyl, and oxime;unsubstituted pyridinyl;substituted pyridinyl with one or two substituents independently selected from the ...

2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS

The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein. 5. A pharmaceutical composition comprising a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.6. A method of treating an HIV infection in a patient in need thereof comprising administering a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the patient.7. A method of treating an HIV infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds claim 1 , HIV non-nucleoside inhibitors of reverse transcriptase claim 1 , HIV nucleoside inhibitors of reverse transcriptase claim 1 , HIV nucleotide inhibitors of reverse transcriptase claim 1 , HIV integrase inhibitors claim 1 , gp41 inhibitors claim 1 , CXCR4 inhibitors claim 1 , gp120 inhibitors claim 1 , CCR5 inhibitors claim 1 , capsid polymerization inhibitors claim 1 , and other drugs for treating HIV.811-. (canceled)12. A pharmaceutical composition comprising a compound as described in claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , and a pharmaceutically acceptable carrier.13. A method of treating an HIV infection in a patient in need thereof comprising administering a compound as ...

NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION

The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein. 9. A pharmaceutical composition comprising a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and a pharmaceutically acceptable carrier.10. A method of treating an HIV infection in a patient in need thereof comprising administering a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the patient.11. A method of treating an HIV infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds claim 1 , HIV non-nucleoside inhibitors of reverse transcriptase claim 1 , HIV nucleoside inhibitors of reverse transcriptase claim 1 , HIV nucleotide inhibitors of reverse transcriptase claim 1 , HIV integrase inhibitors claim 1 , gp41 inhibitors claim 1 , CXCR4 inhibitors claim 1 , gp120 inhibitors claim 1 , CCR5 inhibitors claim 1 , capsid polymerization inhibitors claim 1 , and other drugs for treating HIV.1215-. (canceled)16. A pharmaceutical composition comprising a compound as described in claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , and a pharmaceutically acceptable carrier.17. A method of treating an HIV infection in a patient in need thereof comprising administering a compound as ...

Quinazoline Compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds. 135-. (canceled)37. (canceled)38. A pharmaceutical composition comprising a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof claim 36 , and a pharmaceutically acceptable carrier.39. The pharmaceutical composition of claim 38 , further comprising one claim 38 , two claim 38 , three claim 38 , or four additional therapeutic agents.40. The pharmaceutical composition of claim 39 , wherein the therapeutic agent is independently selected from the group consisting of HIV protease inhibiting compounds claim 39 , HIV non-nucleoside inhibitors of reverse transcriptase claim 39 , HIV nucleoside inhibitors of reverse transcriptase claim 39 , HIV nucleotide inhibitors of reverse transcriptase claim 39 , HIV integrase inhibitors claim 39 , gp41 inhibitors claim 39 , CXCR4 inhibitors claim 39 , gp120 inhibitors claim 39 , CCR5 inhibitors claim 39 , capsid polymerization inhibitors claim 39 , and other drugs for treating HIV claim 39 , and combinations thereof.4143-. (canceled)44. A method for treating an HIV infection in a subject comprising administering to the subject a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof.45. A method for treating an HIV infection in a subject comprising administering to the subject in need thereof a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof claim 36 , in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds claim 36 , HIV non-nucleoside inhibitors of reverse transcriptase claim 36 , HIV nucleoside inhibitors of reverse transcriptase claim 36 , HIV nucleotide inhibitors of reverse transcriptase claim 36 , HIV integrase inhibitors ...

Quinazoline Compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds. 135-. (canceled)37. (canceled)38. A pharmaceutical composition comprising a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof claim 36 , and a pharmaceutically acceptable carrier.39. The pharmaceutical composition of claim 38 , further comprising one claim 38 , two claim 38 , three claim 38 , or four additional therapeutic agents.40. The pharmaceutical composition of claim 39 , wherein the therapeutic agent is independently selected from the group consisting of HIV protease inhibiting compounds claim 39 , HIV non-nucleoside inhibitors of reverse transcriptase claim 39 , HIV nucleoside inhibitors of reverse transcriptase claim 39 , HIV nucleotide inhibitors of reverse transcriptase claim 39 , HIV integrase inhibitors claim 39 , gp41 inhibitors claim 39 , CXCR4 inhibitors claim 39 , gp120 inhibitors claim 39 , CCR5 inhibitors claim 39 , capsid polymerization inhibitors claim 39 , and other drugs for treating HIV claim 39 , and combinations thereof.4143-. (canceled)44. A method for treating an HIV infection in a subject comprising administering to the subject a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof.45. A method for treating an HIV infection in a subject comprising administering to the subject in need thereof a compound of claim 36 , or a tautomer or a pharmaceutically acceptable salt thereof claim 36 , in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds claim 36 , HIV non-nucleoside inhibitors of reverse transcriptase claim 36 , HIV nucleoside inhibitors of reverse transcriptase claim 36 , HIV nucleotide inhibitors of reverse transcriptase claim 36 , HIV integrase inhibitors ...

Quinazoline Compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds. 24-. (canceled)6. (canceled)7. The pharmaceutical composition of claim 1 , wherein X claim 1 , X claim 1 , and Xare each CH.8. (canceled)9. The pharmaceutical composition of claim 1 , wherein X claim 1 , X claim 1 , and Xare C(R); each Rindependently selected from —H claim 1 , —CN claim 1 , —OR claim 1 , halogen claim 1 , and Calkyl; and Ris selected from —H claim 1 , —CN claim 1 , —OR claim 1 , halogen claim 1 , and Calkyl.10. (canceled)11. The pharmaceutical composition of claim 1 , wherein Ris —H claim 1 , —OR claim 1 , —NRR claim 1 , —NHC(O)NRR claim 1 , Calkyl claim 1 , or Cheteroalkyl.12. (canceled)13. The pharmaceutical composition of claim 1 , wherein Ris —NHor —OH.1418-. (canceled)19. The pharmaceutical composition of wherein Ris —H claim 1 , and Ris —H claim 1 , —OR claim 1 , halogen claim 1 , —NO claim 1 , —CN claim 1 , —NRR claim 1 , —NHC(O)NRR claim 1 , or Calkyl.20. (canceled)21. (canceled)22. The pharmaceutical composition of claim 1 , wherein R claim 1 , R claim 1 , and Rare —H.23. The pharmaceutical composition of claim 1 , wherein Ris Calkyl.24. The pharmaceutical composition of claim 1 , wherein Ris Calkyl.25. (canceled)26. (canceled)27. The pharmaceutical composition of claim 1 , wherein Rand Rare Calkyl.28. The pharmaceutical composition of claim 1 , wherein Rand Rare methyl.29. The pharmaceutical composition of claim 1 , wherein Ris —H or Calkyl.30. The pharmaceutical composition of claim 1 , wherein Ris —H or Calkyl.3133-. (canceled)35. (canceled)3743-. (canceled)4551-. (canceled)52. The pharmaceutical composition of claim 1 , wherein one of the additional therapeutic agents is selected from tenofovir alafenamide claim 1 , tenofovir alafenamide fumarate claim 1 , and tenofovir alafenamide hemifumarate.53. The method of claim 44 , wherein one of the ...

Isoquinoline compounds for the treatment of hiv

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

isoquinoline compounds for the treatment of hiv

a presente invenção refere-se a compostos de fórmula (i) e tautômeros e sais farmacêuticos dos mesmos, composições e formulações contendo tais compostos, e métodos de uso e fabricação de tais compostos. The present invention relates to compounds of formula (I) and pharmaceutical tautomers and salts thereof, compositions and formulations containing such compounds, and methods of use and manufacture of such compounds.

Isoquinoline compounds for the treatment of hiv

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Isoquinoline compounds for the treatment of hiv.

Se describen en la presente compuestos de fórmula (I) y tautómeros y sales farmacéuticas de los mismos, composiciones y formulaciones que contienen estos compuestos y métodos de uso y elaboración de estos compuestos.

Quinazoline compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Napthalene acetic acid derivatives against hiv infection

The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

QUINAZOLINE DERIVATIVES USED TO TREAT HIV

SE DESCRIBEN EN EL PRESENTE DOCUMENTO COMPUESTOS DE FÓRMULA (I) Y TAUTÓMEROS Y SALES FARMACÉUTICAS DE LOS MISMOS, COMPOSICIONES Y FORMULACIONES QUE CONTIENEN DICHOS COMPUESTOS, Y MÉTODOS PARA USAR Y PREPARAR DICHOS COMPUESTOS

QUINAZOLINE DERIVATIVES USED TO TREAT HIV

Se describen en el presente documento compuestos de Fórmula (I) y tautómeros y sales farmacéuticas de los mismos, composiciones y Fórmulaciones que contienen dichos compuestos, y métodos para usar y preparar dichos compuestos.

Quinazoline derivatives used to treat hiv

Quinazoline derivatives used to treat hiv

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Pochodne chinazoliny stosowane do leczenia HIV

Derivados de quinazolina usados para tratar el VIH

En el presente documento se describen compuestos de Fórmula (I) y tautómeros y sales farmacéuticas de los mismos, composiciones y formulaciones que contienen dichos compuestos y métodos para usar y preparar dichos compuestos. (Traducción automática con Google Translate, sin valor legal)

Compostos de quinazolina, seus usos, composição farmacêutica, kit, e artigo de manufatura para tratamento ou prevenção de infecções por hiv

compostos de quinazolina a presente invenção refere-se a compostos de fórmula (i) e tautômeros e sais farmacêuticos dos mesmos, composições e formulações que contêm tais compostos e métodos de uso e preparação desses compostos.

Quinazoline derivatives used to treat hiv

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv

Στο παρόν περιγράφονται ενώσεις του τύπου (Ι) και ταυτομερή και φαρμακευτικά άλατα αυτών, συνθέσεις και σκευάσματα που περιέχουν τις εν λόγω ενώσεις, και μέθοδοι χρήσης και παρασκευής των εν λόγω ενώσεων.

Compuestos de quinazolina

Se describen en el presente documento compuestos de Fórmula (I) y tautómeros y sales farmacéuticas de los mismos, composiciones y Fórmulaciones que contienen dichos compuestos, y métodos para usar y preparar dichos compuestos

Quinazoline derivatives used to treat hiv

Quinazoline compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Isoquinoline compounds

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.